학술논문
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
Document Type
Article
Author
González‐López, Tomás José; Alvarez‐Román, María Teresa; Pascual, Cristina; Sánchez‐González, Blanca; Fernández‐Fuentes, Fernando; Jarque, Isidro; Pérez‐Rus, Gloria; Pérez‐Crespo, Susana; Bernat, Silvia; Hernández‐Rivas, José Angel; Andrade, Marcio M.; Cortés, Montserrat; Gómez‐Nuñez, Marta; Olivera, Pavel; Martínez‐Robles, Violeta; Fernández‐Rodríguez, Angeles; Fuertes‐Palacio, Miguel Angel; Fernández‐Miñano, Carmen; Cabo, Erik; Fisac, Rosa
Source
Subject
*IDIOPATHIC thrombocytopenic purpura
*CHRONIC diseases
*HEMORRHAGE
*BLOOD platelets
*IMMUNE response
*
*
*
*
Language
ISSN
0902-4441
Abstract
Background Eltrombopag is effective and safe in chronic immune thrombocytopenia ( ITP). However, clinical trials may not accurately reflect what happens in clinical practice. We evaluated the efficacy and safety of eltrombopag in primary chronic ITP in a real-world setting. Methods A total of 164 primary patients with chronic ITP from 40 Spanish centers, who had been treated with eltrombopag, were retrospectively evaluated. Results The median age of our cohort (72% women) was 63 yr (interquartile range, IQR, 45-75 yr). The median time with ITP diagnosis was 81 months ( IQR, 30-192 months). The median number of therapies prior to eltrombopag was 3 ( IQR, 2-4). At the time of eltrombopag start, 45 patients (30%) were receiving concomitant treatment for ITP. Forty-six patients (30%) had bleeding signs/symptoms the month before the treatment started. The median platelet count at eltrombopag initiation was 22 × 109/L ( IQR, 8-39 × 109/L). A total of 135 patients (88.8%) achieved a platelet response. The median time to platelet response was 12 d (95% CI, 9-13 d). Maintained platelet response rate during the 15-month period under examination was 75.2%. Twenty-eight patients (18.4%) experienced adverse events, mainly grades 1-2. Conclusion Eltrombopag is highly effective and well tolerated in unselected patients with primary chronic ITP. [ABSTRACT FROM AUTHOR]